Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Codon optimization of the adenoviral fiber negatively impacts structural protein expression and viral fitness

  • Villanueva, Eneko
  • Martí Solano, Maria
  • Fillat i Fonts, Cristina
Codon usage adaptation of lytic viruses to their hosts is determinant for viral fitness. In this work, we analyzed the codon usage of adenoviral proteins by principal component analysis and assessed their codon adaptation to the host. We observed a general clustering of adenoviral proteins according to their function. However, there was a significant variation in the codon preference between the host-interacting fiber protein and the rest of structural late phase proteins, with a non-optimal codon usage of the fiber. To understand the impact of codon bias in the fiber, we optimized the Adenovirus-5 fiber to the codon usage of the hexon structural protein. The optimized fiber displayed increased expression in a non-viral context. However, infection with adenoviruses containing the optimized fiber resulted in decreased expression of the fiber and of wild-type structural proteins. Consequently, this led to a drastic reduction in viral release. The insertion of an exogenous optimized protein as a late gene in the adenovirus with the optimized fiber further interfered with viral fitness. These results highlight the importance of balancing codon usage in viral proteins to adequately exploit cellular resources for efficient infection and open new opportunities to regulate viral fitness for virotherapy and vaccine development., This work was supported by grants from the Spanish Ministry of Economia y Competitividad BIO2014-57716-C2-2-R and receives partial support from the Generalitat de Catalunya SGR14/248. CIBER de Enfermedades Raras is an initiative of the ISCIII. CF group is partially financed by the Instituto de Salud Carlos III (IIS10/00014) and co-financed by Fondo Europeo de Desarrollo Regional (FEDER). We also acknowledge the support of COST Action BM1204 EUPancreas. E.V. was supported by a fellowship from the Gobierno Vasco, Spain.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Genome-wide miR-155 and miR-802 target gene identification in the hippocampus of Ts65Dn Down syndrome mouse model by miRNA sponges

  • Bofill-De Ros, Xavier
  • Santos, Mónica
  • Vila-Casadesús, Maria
  • Villanueva, Eneko
  • Andreu Somavilla, Núria
  • Dierssen, Mara
  • Fillat i Fonts, Cristina
Background. Down syndrome (DS) or trisomy 21 is the result of a genetic dosage imbalance that translates in a broad clinical spectrum. A major challenge in the study of DS is the identification of functional genetic elements with wide impact on phenotypic alterations. Recently, miRNAs have been recognized as major contributors to several disease conditions by acting as post-transcriptional regulators of a plethora of genes. Five chromosome 21 (HSA21) miRNAs have been found overexpressed in DS individuals and could function as key elements in the pathophysiology. Interestingly, in the trisomic Ts65Dn DS mouse model two of these miRNAs (miR-155 and miR-802) are also triplicated and overexpressed in brain./nResults. In the current work, we interrogated the impact of miR-155 and miR-802 upregulation on the transcriptome of Ts65Dn brains. We developed a lentiviral miRNA-sponge strategy (Lv-miR155-802T) to identify in vivo relevant miR-155 and miR-802 target mRNAs. Hippocampal injections of lentiviral sponges in Ts65Dn mice normalized the expression of miR-155 and miR-802 and rescued the levels of their targets methyl-CpG-binding protein 2 gene (Mecp2), SH2 (Src homology 2)-containing inositol phosphatase-1 (Ship1) and Forkhead box protein M1 (FoxM1). Transcriptomic data of Lv-miR155-802T miRNA-sponge treated hippocampi correlated with candidate targets highlighting miRNA dosage-sensitive genes. Significant associations were found in a subset of genes (Rufy2, Nova1, Nav1, Thoc1 and Sumo3) that could be experimentally validated./nConclusions. The lentiviral miRNA-sponge strategy demonstrated the genome-wide regulatory effects of miR-155 and miR-802. Furthermore, the analysis combining predicted candidates and experimental transcriptomic data proved to retrieve genes with potential significance in DS-hippocampal phenotype bridging with DS other neurological-associated diseases such as Alzheimer’s disease., This work was supported by grants from Jérôme Lejeune Foundation, Fundació Catalana Síndrome de Down, the Spanish Ministry of Economía y Competitividad BIO2011-30299-C02-02, BIO2014-57716-C2-2-R and SAF2013-49129-C2-1-R, Era Net Neuron Food-for-Thought (PCIN-2013-060), and received partial support from Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya (SGR14/248 and SGR14/1125). CIBERER is an initiative of the ISCIII. CF group is partially financed by ISCIII (IIS10/00014) and co-financed by Fondo Europeo de Desarrollo Regional (FEDER). We acknowledge support from the Spanish Ministry, ‘Centro de Excelencia Severo Ochoa 2013-2017’, SEV-2012-0208. X. Bofill-De Ros and M. Vila were recipients of a FPU fellowship from the Spanish Ministry of Education. E. Villanueva was supported by a fellowship from the Gobierno Vasco, Spain. This work was developed at the Centre Esther Koplowitz, Barcelona, Spain.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Translational reprogramming in tumour cells can generate oncoselectivity in viral therapies

  • Villanueva, Eneko
  • Navarro Medrano, Pilar
  • Rovira-Rigau, Maria
  • Sibilio, Annarita
  • Méndez Giraldez, Raúl
  • Fillat i Fonts, Cristina
Systemic treatment of cancer requires tumour-selective therapies that eliminate cancer cells yet preserve healthy tissues from undesired damage. Tumoral transformation is associated with profound effects in translational reprogramming of gene expression, such that tumour-specific translational regulation presents an attractive possibility for generating oncoselective therapies. We recently discovered that mRNA translational control by cytoplasmic polyadenylation element-binding proteins (CPEBs) is reactivated in cancer. Here we present a novel approach to restrict genetic-engineered therapies to malignant tissues based on CPEB translational regulation of target mRNAs. We demonstrate that tumour reprogramming of CPEB-mediated mRNA stability and translational regulation modulates tumour-specific expression of viral proteins. For oncolytic adenoviruses, insertion of CPE regulatory sequences in the 3'-untranslated region of the E1A gene provides oncoselectivity, with full potency in cancer cells but attenuated in normal tissues. Our results demonstrate the potential of this strategy to improve oncolytic virus design and provide a framework for exploiting CPE-regulated transgenes for therapy., This work was supported by grants to C.F. from the Spanish Ministry of Economia y Competitividad BIO2011-30299-C02-01/02 and BIO2014-57716-C2-2-R, and receives partial support from the Generalitat de Catalunya SGR14/248. CIBER de Enfermedades Raras is an initiative of the ISCIII. The C.F. group is partially financed by the Instituto de Salud Carlos III (IIS10/00014) and cofi-nanced by Fondo Europeo de Desarrollo Regional (FEDER) and also acknowledges the support of COST Action BM1204 EUPancreas and the Spanish Adenovirus Network (AdenoNet, BIO2015-68990-REDT). R.M. received support for this work from the Fundacio´n Botı´n and the Banco Santander, through its Santander Universities Global Division, from the Asociación Española Contra el Cancer (AECC) from the Worldwide Cancer Research Foundation and from the Spanish Ministerio de Economia y Competitividad (BFU2011-30121, BFU2014-54122-P and Consolider RNAREG CSD2009-00080). This work was also supported by grants to P.N. from the Spanish Ministerio de Economía y Competitividad/ISCIII-FEDER (PI14/00125), RETIC Cancer RD12/0036/0051/FEDER and the ‘Generalitat de Catalunya’ (2014/SGR/143). We also acknowledge the support of CERCA Programme/Generalitat de Catalunya. E.V. received a fellowship from the Gobierno Vasco, Spain. This work was developed at the Centro Esther Koplowitz, Barcelona, Spain.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DYRK1A kinase positively regulates angiogenic responses in endothelial cells

  • Rozen, Esteban J.
  • Roewenstrunk, Julia
  • Barallobre, María-José
  • Di Vona, Chiara
  • Jung, Carole
  • Figueiredo, Ana F.
  • Luna, Jeroni
  • Fillat, Cristina
  • Arbones, Maria L.
  • Graupera, Mariona
  • Valverde, Miguel A.
  • Luna, Susana de la
Angiogenesis is a highly regulated process essential for organ development and maintenance, and its deregulation contributes to inflammation, cardiac disorders, and cancer. The Ca2+/nuclear factor of activated T cells (NFAT) signaling pathway is central to endothelial cell angiogenic responses, and it is activated by stimuli like vascular endothelial growth factor (VEGF) A. NFAT phosphorylation by dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) is thought to be an inactivating event. Contrary to expectations, we show that the DYRK family member DYRK1A positively regulates VEGF-dependent NFAT transcriptional responses in primary endothelial cells. DYRK1A silencing reduces intracellular Ca2+ influx in response to VEGF, which dampens NFAT activation. The effect is exerted at the level of VEGFR2 accumulation leading to impairment in PLCγ1 activation. Notably, Dyrk1a heterozygous mice show defects in developmental retinal vascularization. Our data establish a regulatory circuit, DYRK1A/ Ca2+/NFAT, to fine-tune endothelial cell proliferation and angiogenesis, This work was supported by the Spanish Ministry of Economy and Competitiveness (MINECO grants BFU2013-44513 and BFU2016-76141-P to S.L., SAF2015-69762R to M.A.V., SAF2014-59950-P to M.G., BIO2014-57716-C2-R to C.F., and SAF2016-77971-R to M.L.A.), ‘‘La Marato´ de TV3’’ to S.L., the Instituto de Salud Carlos III (IIS10/00014 to C.F. and RD12/0042/0014 to M.A.V.), FEDER Funds to M.A.V., the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674), the European Commission FP7/2007-2013, and 2020 Research and Innovation Programmes (grant agreement 317250 and Marie Sk1odowska-Curie grant agreement 675392). E.J.R., J.L., and M.J.B. are supported by CIBERER, J.R. is an FPI predoctoral fellow (BES-2011- 045867), C.J. is a Juan de la Cierva postdoctoral researcher (JCI-2011- 11140), and A.F.F. is a Marie Sk1odowska-Curie ESR fellow. We acknowledge the support of the MINECO Centro de Excelencia Severo Ochoa and María de Maeztu Programme and the CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth

  • Luna, Jeroni
  • Boni, Jacopo
  • Cuatrecasas, Miriam
  • Bofill-De Ros, Xavier
  • Núñez-Manchón, Estela
  • Gironella, Meritxell
  • Vaquero, Eva C.
  • Arbones, Maria L.
  • Luna, Susana de la
  • Fillat, Cristina
[Background and aims]: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumour with a poor prognosis using current treatments. Targeted therapies may offer a new avenue for more effective strategies. Dual-specificity tyrosine regulated kinase 1A (DYRK1A) is a pleiotropic kinase with contradictory roles in different tumours that is uncharacterised in PDAC. Here, we aimed to investigate the role of DYRK1A in pancreatic tumorigenesis. [Design]: We analysed DYRK1A expression in PDAC genetic mouse models and in patient samples. DYRK1A function was assessed with knockdown experiments in pancreatic tumour cell lines and in PDAC mouse models with genetic reduction of Dyrk1a dosage. Furthermore, we explored a mechanistic model for DYRK1A activity. [Results]: We showed that DYRK1A was highly expressed in PDAC, and that its protein level positively correlated with that of c-MET. Inhibition of DYRK1A reduced tumour progression by limiting tumour cell proliferation. DYRK1A stabilised the c-MET receptor through SPRY2, leading to prolonged activation of extracellular signal-regulated kinase signalling. [Conclusions]: These findings reveal that DYRK1A contributes to tumour growth in PDAC, at least through regulation of c-MET accumulation, suggesting that inhibition of DYRK1A could represent a novel therapeutic target for PDAC., This work was supported by grants from the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) (BIO2014-57716-C2-2-R, BIO2017-89754-C2-2R to CF and BFU2016-76141-P to SL), and receives partial support from the Generalitat de Catalunya (SGR14/248 to CF and SGR14/674 to SL). CIBER de Enfermedades Raras and de Enfermedades Hepáticas y Digestivas are initiatives of the Instituto de Salud Carlos III (ISCIII). The group of CF is partially financed by the ISCIII (IIS10/00014), co-financed by Fondo Europeo de Desarrollo Regional (FEDER), and acknowledges the support of the COST Action BM1204 EUPancreas. MG acknowledges grant PI17/01003 from ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Codon optimization of the adenoviral fiber negatively impacts structural protein expression and viral fitness

  • Villanueva, Eneko
  • Martí Solano, Maria
  • Fillat i Fonts, Cristina
Codon usage adaptation of lytic viruses to their hosts is determinant for viral fitness. In this work, we analyzed the codon usage of adenoviral proteins by principal component analysis and assessed their codon adaptation to the host. We observed a general clustering of adenoviral proteins according to their function. However, there was a significant variation in the codon preference between the host-interacting fiber protein and the rest of structural late phase proteins, with a non-optimal codon usage of the fiber. To understand the impact of codon bias in the fiber, we optimized the Adenovirus-5 fiber to the codon usage of the hexon structural protein. The optimized fiber displayed increased expression in a non-viral context. However, infection with adenoviruses containing the optimized fiber resulted in decreased expression of the fiber and of wild-type structural proteins. Consequently, this led to a drastic reduction in viral release. The insertion of an exogenous optimized protein as a late gene in the adenovirus with the optimized fiber further interfered with viral fitness. These results highlight the importance of balancing codon usage in viral proteins to adequately exploit cellular resources for efficient infection and open new opportunities to regulate viral fitness for virotherapy and vaccine development., This work was supported by grants from the Spanish Ministry of Economia y Competitividad BIO2014-57716-C2-2-R and receives partial support from the Generalitat de Catalunya SGR14/248. CIBER de Enfermedades Raras is an initiative of the ISCIII. CF group is partially financed by the Instituto de Salud Carlos III (IIS10/00014) and co-financed by Fondo Europeo de Desarrollo Regional (FEDER). We also acknowledge the support of COST Action BM1204 EUPancreas. E.V. was supported by a fellowship from the Gobierno Vasco, Spain.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Translational reprogramming in tumour cells can generate oncoselectivity in viral therapies

  • Villanueva, Eneko
  • Navarro Medrano, Pilar
  • Rovira-Rigau, Maria
  • Sibilio, Annarita
  • Méndez Giraldez, Raúl
  • Fillat i Fonts, Cristina
Systemic treatment of cancer requires tumour-selective therapies that eliminate cancer cells yet preserve healthy tissues from undesired damage. Tumoral transformation is associated with profound effects in translational reprogramming of gene expression, such that tumour-specific translational regulation presents an attractive possibility for generating oncoselective therapies. We recently discovered that mRNA translational control by cytoplasmic polyadenylation element-binding proteins (CPEBs) is reactivated in cancer. Here we present a novel approach to restrict genetic-engineered therapies to malignant tissues based on CPEB translational regulation of target mRNAs. We demonstrate that tumour reprogramming of CPEB-mediated mRNA stability and translational regulation modulates tumour-specific expression of viral proteins. For oncolytic adenoviruses, insertion of CPE regulatory sequences in the 3'-untranslated region of the E1A gene provides oncoselectivity, with full potency in cancer cells but attenuated in normal tissues. Our results demonstrate the potential of this strategy to improve oncolytic virus design and provide a framework for exploiting CPE-regulated transgenes for therapy., This work was supported by grants to C.F. from the Spanish Ministry of Economia y Competitividad BIO2011-30299-C02-01/02 and BIO2014-57716-C2-2-R, and receives partial support from the Generalitat de Catalunya SGR14/248. CIBER de Enfermedades Raras is an initiative of the ISCIII. The C.F. group is partially financed by the Instituto de Salud Carlos III (IIS10/00014) and cofi-nanced by Fondo Europeo de Desarrollo Regional (FEDER) and also acknowledges the support of COST Action BM1204 EUPancreas and the Spanish Adenovirus Network (AdenoNet, BIO2015-68990-REDT). R.M. received support for this work from the Fundacio´n Botı´n and the Banco Santander, through its Santander Universities Global Division, from the Asociación Española Contra el Cancer (AECC) from the Worldwide Cancer Research Foundation and from the Spanish Ministerio de Economia y Competitividad (BFU2011-30121, BFU2014-54122-P and Consolider RNAREG CSD2009-00080). This work was also supported by grants to P.N. from the Spanish Ministerio de Economía y Competitividad/ISCIII-FEDER (PI14/00125), RETIC Cancer RD12/0036/0051/FEDER and the ‘Generalitat de Catalunya’ (2014/SGR/143). We also acknowledge the support of CERCA Programme/Generalitat de Catalunya. E.V. received a fellowship from the Gobierno Vasco, Spain. This work was developed at the Centro Esther Koplowitz, Barcelona, Spain.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genome-wide miR-155 and miR-802 target gene identification in the hippocampus of Ts65Dn Down syndrome mouse model by miRNA sponges

  • Bofill-De Ros, Xavier
  • Santos, Mónica
  • Vila-Casadesús, Maria
  • Villanueva, Eneko
  • Andreu Somavilla, Núria
  • Dierssen, Mara
  • Fillat i Fonts, Cristina
Background. Down syndrome (DS) or trisomy 21 is the result of a genetic dosage imbalance that translates in a broad clinical spectrum. A major challenge in the study of DS is the identification of functional genetic elements with wide impact on phenotypic alterations. Recently, miRNAs have been recognized as major contributors to several disease conditions by acting as post-transcriptional regulators of a plethora of genes. Five chromosome 21 (HSA21) miRNAs have been found overexpressed in DS individuals and could function as key elements in the pathophysiology. Interestingly, in the trisomic Ts65Dn DS mouse model two of these miRNAs (miR-155 and miR-802) are also triplicated and overexpressed in brain./nResults. In the current work, we interrogated the impact of miR-155 and miR-802 upregulation on the transcriptome of Ts65Dn brains. We developed a lentiviral miRNA-sponge strategy (Lv-miR155-802T) to identify in vivo relevant miR-155 and miR-802 target mRNAs. Hippocampal injections of lentiviral sponges in Ts65Dn mice normalized the expression of miR-155 and miR-802 and rescued the levels of their targets methyl-CpG-binding protein 2 gene (Mecp2), SH2 (Src homology 2)-containing inositol phosphatase-1 (Ship1) and Forkhead box protein M1 (FoxM1). Transcriptomic data of Lv-miR155-802T miRNA-sponge treated hippocampi correlated with candidate targets highlighting miRNA dosage-sensitive genes. Significant associations were found in a subset of genes (Rufy2, Nova1, Nav1, Thoc1 and Sumo3) that could be experimentally validated./nConclusions. The lentiviral miRNA-sponge strategy demonstrated the genome-wide regulatory effects of miR-155 and miR-802. Furthermore, the analysis combining predicted candidates and experimental transcriptomic data proved to retrieve genes with potential significance in DS-hippocampal phenotype bridging with DS other neurological-associated diseases such as Alzheimer’s disease., This work was supported by grants from Jérôme Lejeune Foundation, Fundació Catalana Síndrome de Down, the Spanish Ministry of Economía y Competitividad BIO2011-30299-C02-02, BIO2014-57716-C2-2-R and SAF2013-49129-C2-1-R, Era Net Neuron Food-for-Thought (PCIN-2013-060), and received partial support from Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya (SGR14/248 and SGR14/1125). CIBERER is an initiative of the ISCIII. CF group is partially financed by ISCIII (IIS10/00014) and co-financed by Fondo Europeo de Desarrollo Regional (FEDER). We acknowledge support from the Spanish Ministry, ‘Centro de Excelencia Severo Ochoa 2013-2017’, SEV-2012-0208. X. Bofill-De Ros and M. Vila were recipients of a FPU fellowship from the Spanish Ministry of Education. E. Villanueva was supported by a fellowship from the Gobierno Vasco, Spain. This work was developed at the Centre Esther Koplowitz, Barcelona, Spain.